GLP-1 Agonists in Older Adults: Key Issues

Around 40% of adults aged 65 and over now live with obesity, and roughly 29% carry a diagnosis of type 2 diabetes^[1]. GLP-1 receptor agonists, including semaglutide and tirzepatide, have reshaped treatment in the general adult population over the past several years. Applying them to older patients, however, raises a distinct set of clinical questions that the pivotal trials were not designed to answer.

A review published in Advances in Therapy in July 2026 by Pendrey and colleagues catalogues the considerations practitioners face when prescribing GLP-1 class medicines to adults with both obesity and type 2 diabetes who are in or approaching older age^[1]. This article draws on that review together with the body-composition substudy data from SURMOUNT-1 and the pivotal SURPASS-1 trial to set out the core issues.

Why older adults are a separate clinical question

The major GLP-1 trials enrolled broad adult populations with mean ages in the early-to-mid 50s^[2][3]. Older adults, defined here as those aged 65 and over, carry a different risk profile: higher rates of polypharmacy, more variable kidney function affecting drug clearance, and a heightened vulnerability to the specific kind of weight loss that GLP-1 agonists produce.

The core tension is that the same appetite suppression and gastric slowing that produces weight loss in a 50-year-old with obesity may tip an older patient into a caloric deficit that costs them lean mass they cannot easily recover. Obesity in older adults already coexists with age-related muscle decline (sarcopenia), and a large weight-loss intervention can accelerate both processes at once.

The sarcopenia concern

Body-composition data from SURMOUNT-1 showed that weight loss with tirzepatide at 72 weeks broke down as approximately 75% fat mass and 25% lean mass, a ratio broadly consistent with what is seen on placebo at the lower weight-loss levels^[4]. Across the study population that proportion held regardless of age group.

For a younger adult losing 20% of body weight, a 25% lean-mass component may be clinically acceptable. For a patient aged 70 who already has reduced muscle mass relative to their younger self, the same proportion of lean loss can represent a meaningful functional decline. Walking speed, grip strength, and the ability to recover from illness are all tied to skeletal muscle reserves that are harder to rebuild in older age.

The practical implication is not that GLP-1 agonists are contraindicated in older patients, but that clinicians managing them should monitor lean mass and physical function more actively, and that resistance exercise and adequate protein intake alongside pharmacotherapy matter more in this group than in a younger cohort.

Gastrointestinal side effects and nutrition

Nausea, vomiting, diarrhoea, and constipation are the most common adverse events across the GLP-1 class^[2]. In the general SURPASS and SURMOUNT trial populations these were largely mild to moderate and transient, resolving with dose titration. In older patients, the same events carry a greater downstream risk.

Repeated nausea or vomiting that reduces food intake in a patient already eating a limited diet can tip into undernutrition. Diarrhoea raises dehydration risk, which is more consequential in older adults whose kidney function and fluid regulation are already less resilient. These are not theoretical risks; they are the reason the Pendrey review flags gastrointestinal management as a priority consideration rather than a background caveat.

Polypharmacy and drug interactions

Older adults with both obesity and type 2 diabetes are typically managing several conditions at once and carrying correspondingly large medication lists^[1]. GLP-1 agonists delay gastric emptying, which affects the absorption timing of co-administered oral medicines. Drugs with narrow therapeutic windows, including warfarin or some antiepileptics, may require monitoring adjustments when a GLP-1 agonist is introduced.

Hypoglycaemia risk is another interaction point. GLP-1 agonists alone have a low intrinsic hypoglycaemia risk, but when combined with sulfonylureas or insulin, they can lower blood glucose further. In older adults, hypoglycaemia is particularly hazardous because the counter-regulatory response is blunted and fall risk is elevated. Dose adjustments to other glucose-lowering agents when initiating a GLP-1 agonist are a standard precaution that assumes added importance in this age group.

What the evidence does and does not tell us

The Pendrey review concludes that GLP-1 receptor agonists represent a valuable treatment option for older adults with obesity and type 2 diabetes, but it is explicit that the evidence base specific to this age group is limited^[1]. The pivotal trials were not powered or designed to detect age-specific differences in efficacy or safety. Dedicated trials in older populations remain largely absent from the published literature.

What we do know: GLP-1 agonists produce meaningful glycaemic control and weight reduction across the adult age range represented in existing trials. The SURPASS programme showed HbA1c reductions of 1.87% to 2.07% with tirzepatide monotherapy across a population whose mean age was in the mid-50s^[2]. Whether these numbers translate proportionally to adults aged 75 and above, and at what cost to lean mass and functional status, is an open question.

This is not a reason to withhold treatment from older patients who meet the criteria for GLP-1 therapy. It is a reason to treat the clinical picture as more complex than the trial summaries alone suggest, to titrate slowly, to monitor functional outcomes alongside weight and glycaemic markers, and to involve the patient in an explicit discussion of trade-offs.

A note on what this article cannot answer

This is an educational summary of a published review and the available trial data. It is not clinical guidance. Decisions about whether to start, continue, or adjust a GLP-1 agonist in any individual older patient, including questions about starting dose, titration pace, monitoring frequency, and the interaction with existing medicines, belong with a clinician who knows that patient's full history. For regulatory status by country, see the tirzepatide regulation pages and the semaglutide page for the broader GLP-1 class context.